Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.

Piero RuggenentiMatias TrilliniDrazenka P BarlovicMonica CortinovisAntonio PisaniAneliya ParvanovaIlian P IlievBarbara RuggieroStefano RotaMaria C AparicioAnnalisa PernaFrancesco PeraroOlimpia DiadeiFlavio GaspariFabiola CarraraNadia StucchiDavide MartinettiAndrej JanezNadan GregoricEleonora RiccioAntonio C BossiRoberto TrevisanPaolo ManuntaGiovanni BattagliaSalvatore DavidFilippo AucellaAntonio BelvisoAndrea SattaGuiseppe Remuzzinull null

Published in: Diabetes, obesity & metabolism (2019)

In people with type 2 diabetes with nephropathy, valsartan (320 mg/d) safely postponed ESRD more effectively than benazepril (20 mg/d) or than halved doses of both medications.

Keyphrases

randomized controlled trial
study protocol
end stage renal disease
peritoneal dialysis